Effect of CBX4/miR-137/Notch1 signaling axis on the proliferation and migration of breast cancer cells
Abstract
Purpose: To study the effect of CBX4/miR-137/Notch1 signaling axis on the migration and proliferative capacity of breast cancer.
Methods: Breast cancer MCF7 cell lines were cultured in vitro and transfected with CBX4- overexpressed plasmid and interfering plasmid, which served as CBX4 over-expressing group and CBX4 interfering group, respectively. A control group (blank plasmid transfection) was set up. The MCF7 cells were transfected with miR-137 over-expressed plasmid, miR-137 interfering plasmid and Notch1 interfering plasmid, which served as miR-137 over-expressing, miR-137 interference and Notch1 interference groups, respectively. Cell proliferation and migration capacity were determined with methylthiazolyldiphenyl-tetrazolium (MTT) method and Transwell migration assay, respectively, while reverse transcription-polymerase chain reaction (RT-PCR) and immunoblotting were used to assay related gene expressions.
Results: Cell migration in CBX4 over-expressing group was significantly raised (p < 0.05). The expression of miR-137 in CBX4 over-expressing group was markedly decreased (p < 0.05). Compared with the control group, mRNA and protein expressions of Notch1 (NICD), Hey2 and Jag1 in miR-137 over-expressing cells were increased in the miR-137 interfering group (p < 0.05).
Conclusion: CBX4 level is increased in mammary cancer cells. Moreover, CBX4 enhances cell proliferation and migration through induction of Notch1 signaling route by inhibiting miR-137 expression. These findings provide a new strategy for clinical therapy of mammary cancer.
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
